The Filing Desk

Lineage Cell Therapeutics vs MediWound

Lineage Cell Therapeutics LCTX · MediWound MDWD · Biotechnology

MediWound reported revenue of $17 million in fiscal 2025, 1.2 times Lineage Cell Therapeutics' $15 million in fiscal 2025. Lineage Cell Therapeutics' revenue grew 53.2% in its latest year, and MediWound's fell 16.1%. Lineage Cell Therapeutics had an operating margin of -251.6%, against -149.0% at MediWound. Free cash flow was −$19 million at Lineage Cell Therapeutics and −$22 million at MediWound.

Side by side

Lineage Cell TherapeuticsMediWound
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$15M$17M
Revenue growth53.2%−16.1%
Revenue growth a year, last 5 years52.0%−4.9%
Gross margin—19.2%
Operating margin−251.6%−149.0%
Net margin−436.5%−140.8%
Free cash flow−$19M−$22M
Free cash flow margin−133.6%−127.5%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count14.9%14.2%
Last close$0.82$13.54
P/E at the last close——
Insider trades, last 12 monthsbought $878,348, sold $0—
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Lineage Cell TherapeuticsMediWound
Operating margin
Percent of revenue
Lineage Cell TherapeuticsMediWound
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Lineage Cell TherapeuticsMediWound

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Lineage Cell Therapeutics and MediWound pages.